Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Neurotrophic Factor Therapies for Parkinson's Disease, 2010
    Intermittent Bilateral Intraputamenal Treatment with GDNF

    Objective/Rationale
    Glial cell-derived neurotrophic factor (GDNF) has been shown in various pre-clinical models of Parkinson's disease (PD) to restore damaged nerve cells, including dopamine...

  • Therapeutics Development Initiative, 2010
    Flibanserin in Levodopa-induced Dyskinesia: MPTP-lesioned Pre-clinical Model

    Objective/Rationale
    Different mechanisms of action are considered relevant for provoking the involuntary abnormal jerking and hyperextensive or writhing-like twisting and turning movements called...

  • Therapeutics Development Initiative, 2010
    Investigation of PDE10a Inhibitors for Parkinsons Disease.PI is Bart Ellenbroek

    Objective/Rationale:
    Phosphodiesterase 10A (PDE10A) is an intracellular protein that is located almost exclusively within the basal ganglia. It plays an important role in information transfer within...

  • Therapeutics Development Initiative, 2010
    Targeting alpha-synuclein-lipid interactions in preclinical Parkinson's disease models

    Objective/Rationale:
    Parkinson’s disease is caused by loss of dopaminergic neurons in significant part secondary to accumulation/aggregation of a protein called a-synuclein. New information has shown...

  • Therapeutics Development Initiative, 2010
    Assessment of the Neurorestorative Potential of Enhanced Neurotrophic Support via Positive Glutamatergic Modulation in the MPTP Pre-clinical Model of PD

    Objective/Rationale:
    Parkinson’s is a neurodegenerative disease of the part of the brain that controls motor function. Brain-derived neurotrophic factors promote survival of dopaminergic neurons...

  • Therapeutics Development Initiative, 2010
    Optimization of Selective Mu Opioid Receptor Antagonists for the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease

    Promising Outcomes of Original Grant:
    The major objectives of the original grant were to improve upon the μ receptor (MOR) selectivity of ADC5510 and to find compounds that had superior pharmacokinetic...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.